NWBO NORTHWEST BIOTHERAPEUTICS INC
Pharmaceutical Preparations · OTC · SEC CIK 1072379 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY204.8%
TTM net income YoY55.8%
TTM EPS YoY50.0%
Revenue 3-yr CAGR11.1%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-1,608.8%
Net margin-1,388.8%
FCF margin-1,557.6%
EBITDA margin-1,517.8%
Returns
ROE—
ROA-74.3%
ROIC (approx.)—
Asset turnover0.05x
Leverage & solvency
Liabilities / assets160.8%
Debt / equity—
Current ratio0.03x
Interest coverage-4.89x
Cash quality & payout
Operating cash flow / net income1.09x
Accruals ratio6.6%
Payout ratio—
Capex / revenue45.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $883,000 | $807,000 | $494,000 | $672,000 | $200,000 | $131,000 | $375,000 | $231,000 |
| R&D expense | $4.22M | $5.71M | $4.86M | $5.55M | $7.45M | $7.43M | $8.35M | $10.52M |
| SG&A expense | $6.60M | $6.71M | $6.54M | $8.62M | $7.07M | $7.48M | $9.34M | $8.21M |
| Operating income | -$9.94M | -$11.61M | -$10.90M | -$13.50M | -$14.32M | -$14.78M | -$17.31M | -$18.50M |
| Interest expense | $2.60M | $1.81M | $2.35M | $2.65M | $2.62M | $1.83M | $1.60M | $2.49M |
| Net income | -$28.76M | -$9.22M | -$3.07M | $1.39M | -$26.83M | -$15.38M | -$19.34M | -$28.22M |
| EBITDA | -$9.34M | -$11.11M | -$10.13M | -$12.78M | -$13.92M | -$14.28M | -$16.88M | -$18.05M |
| EPS (basic) | -0.02 | -0.01 | 0.00 | — | -0.02 | -0.01 | -0.01 | — |
| EPS (diluted) | -0.02 | -0.01 | 0.00 | — | -0.02 | -0.01 | -0.01 | — |
| Weighted avg. shares (diluted) | 1.71B | 1.64B | 1.58B | — | 1.49B | 1.44B | 1.36B | — |
| Balance sheet | ||||||||
| Cash & equivalents | $725,000 | $595,000 | $1.79M | $3.04M | $4.56M | $4.32M | $2.78M | $2.17M |
| Current assets | $2.43M | $2.57M | $6.20M | $5.52M | $7.20M | $6.16M | $4.69M | $4.06M |
| PP&E, net | $16.07M | $16.48M | $16.77M | $17.41M | $16.87M | $16.68M | $16.29M | $16.20M |
| Goodwill | $626,000 | $626,000 | $626,000 | $626,000 | $626,000 | $626,000 | $626,000 | $626,000 |
| Intangibles | $51.78M | $51.93M | $52.05M | $53.19M | — | — | — | $1.29M |
| Total assets | $76.14M | $75.94M | $80.05M | $81.29M | $30.61M | $29.55M | $27.50M | $26.73M |
| Current liabilities | $90.94M | $73.35M | $82.97M | $91.70M | $87.91M | $83.92M | $83.06M | $68.27M |
| Long-term debt | $64.51M | $51.97M | $59.43M | $60.04M | $72.20M | $64.74M | $64.14M | $62.68M |
| Total debt | $64.51M | $51.97M | $59.43M | $60.04M | $72.20M | $64.74M | $64.14M | $62.68M |
| Total liabilities | $122.44M | $110.72M | $118.11M | $128.86M | $125.86M | $116.18M | $112.34M | $105.71M |
| Shareholders' equity | -$56.70M | -$45.17M | -$50.54M | -$60.28M | -$108.65M | -$100.39M | -$99.48M | -$94.49M |
| Net debt | $63.79M | $51.38M | $57.64M | $57.00M | $67.64M | $60.42M | $61.37M | $60.50M |
| Shares outstanding | 1.76B | 1.67B | 1.61B | 1.56B | 1.52B | 1.46B | 1.39B | 1.33B |
| Cash flow statement | ||||||||
| Operating cash flow | -$8.76M | -$7.17M | -$12.51M | -$14.76M | -$13.89M | -$6.69M | -$9.42M | -$20.18M |
| Capital expenditure | $53,000 | $198,000 | $129,000 | $905,000 | $202,000 | $304,000 | $93,000 | $78,000 |
| Free cash flow | -$8.81M | -$7.37M | -$12.64M | -$15.67M | -$14.10M | -$6.99M | -$9.51M | -$20.26M |
| Investing cash flow | -$53,000 | -$198,000 | -$129,000 | -$905,000 | -$513,000 | -$304,000 | -$93,000 | -$78,000 |
| Financing cash flow | $8.63M | $7.37M | $9.21M | $13.59M | $11.56M | $12.45M | $11.73M | $15.94M |
| Depreciation & amortization | $600,000 | $500,000 | $771,000 | $728,000 | $400,000 | $500,000 | $434,000 | $444,000 |
| Stock-based compensation | $148,000 | $181,000 | $288,000 | $185,000 | $273,000 | $364,000 | $385,000 | $476,000 |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.